BioPharma « Terug naar discussie overzicht

INSM - Insmed - 2009 draadje

3.044 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ... 149 150 151 152 153 » | Laatste
[verwijderd]
0
quote:

psycho-pharma schreef:

Gestaag, gestaag
...Ach P., gestaag $12,400 verdienen is ook wel'ns lekker ;-)

Geluk, F.
[verwijderd]
0
quote:

SPIKY schreef:

en we gaan weer lekker richting de $1,77
fijn bij verzwakkende dollar
:p
[verwijderd]
0
quote:

crackedtooth schreef:

[quote=SPIKY]
en we gaan weer lekker richting de $1,77
[/quote]

fijn bij verzwakkende dollar
:p
maakt me niks uit hou toch voorlopig het geld in de usa
[verwijderd]
0
spiky: dan nog... longterm grote kans op blijvend zwakkere dollar tov euro..

dat je in US geinvesteerd blijft, wil niet zeggen dat je waarde in euros niet bij een sterkere dollar wilt locken
[verwijderd]
0
quote:

SPIKY schreef:

ik vind het stil hier ondanks toch weer een mooie stijging
Ga toch echt nie binnen achter de pc zitten met dit weer.... en de sleeptop heeft een accu die het met moeite 15 minuten volhoudt....

Prettig weekend !

Riel
ludwig mack
0
[verwijderd]
0
Vandaag weer mijn INSM met zo'n uitgebreid.
Gemiddelde aankoopprijs nu $ 0,49

Oh ja, ook prettig weekend
[verwijderd]
0
After Hours
Last: $ 1.68 After Hours
High: $ 1.80
After Hours
Volume: 6,200 After Hours
Low: $ 1.63

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18:05 $ 1.68 500
16:51 $ 1.63 100
16:08 $ 1.74 100
16:08 $ 1.80 100
16:08 $ 1.80 100
16:08 $ 1.75 100
16:08 $ 1.75 100
16:08 $ 1.75 100
16:04 $ 1.72 1,000
16:04 $ 1.72 797
16:02 $ 1.70 3,203

eerst 1,75 zag ik ook en toen dit nog

[verwijderd]
0
quote:

SPIKY schreef:

After Hours
Last: $ 1.68 After Hours
High: $ 1.80
After Hours
Volume: 6,200 After Hours
Low: $ 1.63

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18:05 $ 1.68 500
16:51 $ 1.63 100
16:08 $ 1.74 100
16:08 $ 1.80 100
16:08 $ 1.80 100
16:08 $ 1.75 100
16:08 $ 1.75 100
16:08 $ 1.75 100
16:04 $ 1.72 1,000
16:04 $ 1.72 797
16:02 $ 1.70 3,203

eerst 1,75 zag ik ook en toen dit nog

Gezien het volume zegt dit niet zo veel. Maar hopen dat er de komende week een aanloop gaat komen.
junkbond
1
Neoadjuvant, Multiple Dose, Dose Escalation Phase 1 Trial of the Clinical Safety and Molecular Efficacy of rhIGFBP-3 in Subjects with High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy (IRB # 07-02-091) Study purpose:
The optimal treatment for patients with locally advanced prostate cancer is particularly controversial. Both radiation therapy and radical prostatectomy have been used to treat advanced prostate cancer either alone or in combination. These approaches have significant limitations in their ability to eliminate locally advanced prostate cancer. Therefore, we desperately need new approaches to treating these patients that hold more promise for long-term local control. We propose to study the use of recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) prior to radical prostatectomy, to improve the results of surgery for high-risk patients. This therapy is not yet approved by the US Food and Drug Administration (FDA).

The purpose of this study is to evaluate the safety and effectiveness of rhIGFBP-3 prior to radical prostatectomy. Pre-study tumor biopsies used to establish diagnosis and post-study medication surgical specimens will be analyzed for different biomarkers. Biomarkers are substances in the body fluids or tissues whose levels can indicate if the study medication is having an effect in your body. This is a phase I study. The purpose of a phase I study is to find the best way to give an experimental product and how much of it can be given safely In this study, subjects will be assigned to groups that correspond with increasing doses of the study drug. Physicians watch subjects carefully for any harmful side effects.
clinicaltrials.ucla.edu/body.cfm?xyzp...
junkbond
1
Unraveling IGFBP-3 Actions in Human Disease

The IGF system plays critical roles in somatic growth in an endocrine fashion (somatomedin hypothesis) as well as proliferation and differentiation of normal and malignant cells in a paracrine/autocrine fashion. IGFBP-3 is known to modulate the actions of IGFs in circulation as well as the immediate extracellular environment. Interestingly, apart from the ability to inhibit or enhance IGF actions, IGFBP-3 also exhibits very clear, distinct biologic effects independent of the IGF/IGF-I receptor axis. Over the past decade it has become widely appreciated that IGF/IGF-IR-independent actions of IGFBP-3 (antiproliferative and pro-apoptotic effects) contribute to improving the pathophysiology of a variety of human diseases such as cancer, diabetes and malnutrition. Recent studies have implicated interaction of IGFBP-3 with a variety of proteins or signaling cascades critical to cell cycle control and apoptosis, however, the actual mechanism of IGFBP-3 action is still unclear. This review reinforces the concept in support of the IGF/IGF-IR axis-independent actions of IGFBP-3 and delineates potential underlying mechanisms involved and subsequent biological significance, focusing in particular on functional binding partners and the clinical significance of IGFBP-3 in the assessment of cancer risk.

sorry maar de Link wil niet.
3.044 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ... 149 150 151 152 153 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
910,36  -4,59  -0,50%  13:38
 Germany40^ 18.677,40 -0,49%
 BEL 20 3.970,71 -0,90%
 Europe50^ 5.036,78 -0,74%
 US30^ 39.839,50 +0,00%
 Nasd100^ 18.677,50 -0,06%
 US500^ 5.313,00 +0,01%
 Japan225^ 38.997,40 -0,78%
 Gold spot 2.419,72 -0,27%
 EUR/USD 1,0866 +0,08%
 WTI 78,03 -1,49%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Flow Traders +1,79%
SBM Offshore +1,37%
OCI +0,81%
NSI +0,51%
Eurocommercia... +0,45%

Dalers

Alfen N.V. -14,75%
Sif Holding -4,24%
AMG Critical ... -3,95%
FASTNED -3,65%
EBUSCO HOLDING -2,94%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront